Lupin Acquires UK's Renascience Pharma for £12.3 Million to Strengthen Branded Portfolio

　　【Pharmaceutical Network Industry DynamicsRecently, Indian pharmaceutical company Lupin announced the acquisition of UK-based Renascience Pharma for £12.3 million, obtaining full ownership of the company. Through this acquisition, Lupin will strengthen its branded drug portfolio and expand its reach, thereby improving patient outcomes.
 

Public information shows that Lupin is an innovation-driven pharmaceutical company that develops and commercializes a wide range of branded and generic formulations, biotechnology products, and more in over 100 markets across the United States, India, South Africa, as well as the Asia-Pacific (APAC), Latin America (LATAM), Europe, the Middle East, and other regions.Active Pharmaceutical Ingredients(API). Lupin's main focus areas include pediatrics, cardiovascular, anti-infectives, diabetes, asthma, and anti-tuberculosis drugs. In recent years, Lupin has been actively promoting its global expansion strategy, with operations spanning multiple countries and regions across six continents. Through strategic acquisitions and entering new markets, the company continues to expand its global business footprint.
 

On August 18, 2023, pharmaceutical company Lupin announced that it had acquired the diabetes brands Ondero (linagliptin) and Ondero Met (linagliptin and metformin) from Boehringer Ingelheim for €26 million (INR 2.35 billion), including the trademark rights associated with these brands, in an all-cash transaction. Lupin stated that this acquisition is expected to add value to the company's diabetes portfolio. As part of a co-marketing agreement with Boehringer Ingelheim India, Lupin has been selling Ondero and Ondero Met in the Indian market since 2015.
 

India's pharmaceutical industry is dominated by generic drugs, with 90% of companies primarily engaged in the production of generics. In recent years, with the continuous advancement of innovative drug research and development and the growing global health demands, India's pharmaceutical enterprises are facing significant development opportunities. To enhance market competitiveness, many companies are accelerating strategic acquisitions.
 

For instance, on March 10 this year, Sun Pharma, a major Indian pharmaceutical company, agreed to acquire Checkpoint Therapeutics (CKPT.US), an American immuno-oncology company, for an upfront payment of $355 million to strengthen its specialty therapeutics portfolio. It is reported that in recent years, the company has been continuously expanding through a series of mergers and acquisitions. In addition to acquiring Checkpoint Therapeutics, it also acquired Ranbaxy Laboratories, an Indian pharmaceutical company, in 2014, and Concert Pharmaceuticals, headquartered in the U.S., in 2023.
 

In early March, Granules announced that it would acquire Swiss CDMO company Senn Chemicals for $22 million, officially entering the peptide therapeutics market. The transaction is expected to be completed in the first half of this year. Granules stated in a press release that Senn Chemicals possesses deep expertise and a mature technology platform in the fields of Liquid Phase Peptide Synthesis (LPPS) and Solid Phase Peptide Synthesis (SPPS), and this acquisition will provide strong support for Granules to quickly enter the peptide therapeutics market.
 

In July 2024, Mankind Pharma acquired all shares of biopharmaceutical company Bharat Serums and Vaccines Limited (BSV) for $1.63 billion to strengthen its market position in women's health and fertility and gain access to high-barrier products in the critical care field.
 

　　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.